ZDHHC9 and breast carcinoma: Disrupting PD-L1 palmitoylation through specific point mutations at the Cys272 site or inhibiting ZDHHC9 expression makes breast cancer cells sensitive to T-cell killing, thereby inhibiting tumor growth [299].